Credit Suisse Ag Avrobio, Inc. Transaction History

Credit Suisse Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$0.75 - $1.33 $15 - $26	20 New	20 $0
Q4 2021 Feb 14, 2022	SELL	$3.45 - $6.05 $68,178 - $119,560	-19,762 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$5.53 - $9.28 $14,969 - $25,120	2,707 Added 15.87%	19,762 $110,000
Q2 2021 Aug 16, 2021	SELL	$7.84 - $12.6 $44,374 - $71,316	-5,660 Reduced 24.92%	17,055 $151,000
Q1 2021 May 14, 2021	SELL	$10.54 - $19.3 $258,409 - $473,178	-24,517 Reduced 51.91%	22,715 $288,000
Q4 2020 Feb 12, 2021	BUY	$12.79 - $17.1 $138,298 - $184,902	10,813 Added 29.69%	47,232 $657,000
Q3 2020 Nov 13, 2020	SELL	$12.99 - $19.41 $49,128 - $73,408	-3,782 Reduced 9.41%	36,419 $474,000
Q2 2020 Aug 12, 2020	BUY	$12.19 - $22.96 $71,250 - $134,201	5,845 Added 17.01%	40,201 $701,000
Q1 2020 May 13, 2020	BUY	$10.08 - $27.21 $208,010 - $561,505	20,636 Added 150.41%	34,356 $535,000
Q4 2019 Feb 12, 2020	SELL	$13.05 - $21.88 $25,108 - $42,097	-1,924 Reduced 12.3%	13,720 $277,000
Q3 2019 Nov 12, 2019	BUY	$14.12 - $23.44 $220,893 - $366,695	15,644 New	15,644 $221,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.